Ibopamine | CAS#66195-31-1 | sympathomimetic agent

MedKoo Cat#: 461851 | Name: Ibopamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology. It induces mydriasis -- dilation of the pupil of the eye.

Chemical Structure

Ibopamine

CAS#66195-31-1 (free base)

Theoretical Analysis

MedKoo Cat#: 461851

Name: Ibopamine

CAS#: 66195-31-1 (free base)

Chemical Formula: C17H25NO4

Exact Mass: 307.1784

Molecular Weight: 307.39

Elemental Analysis: C, 66.43; H, 8.20; N, 4.56; O, 20.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

75011-65-3 (HCl) 66195-31-1 (free base) 66195-35-5 (HBr) 106175-82-0 (citrate) 862420-20-0 (maleate))

Synonym

Ibopamine; Ibopamino; Ibopaminum; SB 7505; SB-7505; SB7505;

IUPAC/Chemical Name

4-(2-(methylamino)ethyl)-1,2-phenylene bis(2-methylpropanoate)

InChi Key

WDKXLLJDNUBYCY-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3

SMILES Code

CNCCC1=CC=C(OC(C(C)C)=O)C(OC(C(C)C)=O)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 307.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Landers J, Ullrich K, Craig JE. Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases. Clin Exp Ophthalmol. 2015 Dec;43(9):808-14. doi: 10.1111/ceo.12569. Epub 2015 Jul 27. PubMed PMID: 26140527. 2: Landers J, Ullrich K, Craig JE. Ibopamine challenge testing becomes negative following successful trabeculectomy surgery. Clin Exp Ophthalmol. 2016 Apr;44(3):166-9. doi: 10.1111/ceo.12684. Epub 2016 Feb 12. PubMed PMID: 26575026. 3: Domínguez-Dueñas F, Plaza-Espinosa L, Mundo-Fernández EE, Jiménez-Reynoso CA, Barojas-Weber E, Barrientos-Gutiérrez T. Early Glaucoma Screening Using the Ibopamine Provocative Test. J Glaucoma. 2016 May;25(5):e441-5. doi: 10.1097/IJG.0000000000000343. PubMed PMID: 26709501. 4: Ullrich K, Craig JE, Landers J. Ibopamine challenge test can be used to differentiate glaucoma suspects from glaucoma patients. Clin Exp Ophthalmol. 2014 May-Jun;42(4):342-6. doi: 10.1111/ceo.12200. Epub 2013 Oct 8. PubMed PMID: 24034130. 5: Virno M, Sampaolesi R, Pecori Giraldi J, De Gregorio F, Taloni M, Brusini P, Di Staso S, Stecchi G. Ibopamine: D1-dopaminergic agonist in the diagnosis of glaucoma. J Glaucoma. 2013 Jan;22(1):5-9. doi: 10.1097/IJG.0b013e3182311db4. PubMed PMID: 21946546. 6: Giuffrè I, Falsini B, Gari MA, Balestrazzi E. Pattern electroretinogram assessment during ibopamine test in ocular hypertension. Eur J Ophthalmol. 2013 Nov-Dec;23(6):819-22. doi: 10.5301/ejo.5000334. Epub 2013 Jun 24. PubMed PMID: 23813108. 7: Bhosai SJ, Lin CC, Greene J, Bloomer MM, Jeng BH. Rapid corneal adrenochrome deposition from topical ibopamine in the setting of infectious keratitis. Eye (Lond). 2013 Jan;27(1):105-6. doi: 10.1038/eye.2012.217. Epub 2012 Oct 19. PubMed PMID: 23079754; PubMed Central PMCID: PMC3545386. 8: Scuderi GL, Regine F, Perdicchi A, Turtoro A, Contestabile MT. Efficacy of 2% ibopamine on the dilation of patients with pseudoexfoliation syndrome. Eur J Ophthalmol. 2010 Jan-Feb;20(1):120-3. PubMed PMID: 19882519. 9: Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, van Meurs JC. Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. Retina. 2012 Apr;32(4):742-7. doi: 10.1097/IAE.0b013e3182265177. PubMed PMID: 21909052. 10: Alicandri C, Fariello R, Boni E, Zaninelli A, Muiesan G. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. J Cardiovasc Pharmacol. 1989;14 Suppl 8:S77-82. PubMed PMID: 2483444. 11: Girbes AR, Van Veldhuisen DJ, Grevink RG, Smith AJ, Reitsma WD. Effects of ibopamine on exercise-induced increase in norepinephrine in normal men. J Cardiovasc Pharmacol. 1992 Mar;19(3):371-4. PubMed PMID: 1378116. 12: Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study. G Ital Cardiol. 1989 Jan;19(1):71-80. PubMed PMID: 2663585. 13: Wehling M, Zimmermann J, Weil J, Gerzer R, Theisen K. [Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure]. Z Kardiol. 1990 Feb;79(2):120-5. German. PubMed PMID: 2157313. 14: Parker JO. The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol. 1993 Jul 15;40(3):221-7. PubMed PMID: 8225657. 15: Pigini MA, Avila MP, Magacho L. [Effects of 2% ibopamine eye drops on the results of computerized visual field]. Arq Bras Oftalmol. 2009 May-Jun;72(3):365-9. Portuguese. PubMed PMID: 19668968. 16: Pouleur H. Neurohormonal and hemodynamic effects of ibopamine. Clin Cardiol. 1995 Mar;18(3 Suppl I):I17-21. Review. PubMed PMID: 7743694. 17: Spencer C, Faulds D, Fitton A. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs Aging. 1993 Nov-Dec;3(6):556-84. Review. PubMed PMID: 7906158. 18: Azzollini F, De Caro L, Longo A, Pelosi G, Rolandi E, Ventresca GP, Lodola E. Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure. Int J Clin Pharmacol Ther Toxicol. 1988 Nov;26(11):544-51. PubMed PMID: 3243658. 19: van Gilst WH, van Veldhuisen DJ, Hegeman H, Buikema H, Scholtens E, de Graeff PA, Lie KI. Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril. J Cardiovasc Pharmacol. 1994 Jul;24(1):171-4. PubMed PMID: 7521484. 20: Lieverse AG, van Veldhuisen DJ, Smit AJ, Zijlstra JG, Meijer S, Reitsma WD, Lie KI, Girbes AR. Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. J Cardiovasc Pharmacol. 1995 Mar;25(3):361-7. PubMed PMID: 7769799.